InsidersTradesSigma
Follow the Evofem Biosciences, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Evofem Biosciences, Inc. has recorded 23 public disclosures. Market capitalisation: €1.1m. The latest transaction was filed on 31 May 2022 (Acquisition). Among the most active insiders: PELLETIER SAUNDRA L. Every trade is free.
23
Insider Decl.
n/a
Thresholds
€225,325
11 ops.
Buy Volume
n/a
3 ops.
Sell Volume
63Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 16,134 of 29,063 companies
48.9
score / 100
Value37
Quality61
FCF yld-188%
Earn yld26%
EV/EBITDA26.9x
ROE·
Gross mgn77%
Net mgn1.4%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 31 May 2022
Declarations23 total
141,000 shares@ US$0.35255.38% mcap15.7% of flowCommon StockSEC:0001618835-22-000130:0
Canonical exit: 25 Aug 2022 (T+90)
750,000 shares0Common StockSEC:0001618835-22-000028:0
300,000 shares0Common StockSEC:0001618835-22-000031:0
450,000 shares0Common StockSEC:0001618835-22-000030:0
300,000 shares0Common StockSEC:0001618835-22-000004:0
120,000 shares0Common StockSEC:0001618835-22-000005:0
120,000 shares0Common StockSEC:0001618835-22-000006:0
40,594 shares@ US$0.371.55% mcap13.6% of flowCommon StockSEC:0001618835-21-000272:0
Canonical exit: 20 Mar 2022 (T+90)
25,000 shares@ US$0.3891.00% mcap9.3% of flowCommon StockSEC:0001618835-21-000273:0
Canonical exit: 20 Mar 2022 (T+90)
135,000 shares@ US$0.3755.23% mcap15.3% of flowCommon StockSEC:0001618835-21-000271:0
Canonical exit: 20 Mar 2022 (T+90)
19,998 shares@ US$0.97529.6% of flowCommon StockSEC:0001618835-21-000158:0
10,000 shares@ US$1.165100.0% of flowCommon StockSEC:0001618835-21-000156:0
Canonical exit: 16 Sept 2021 (T+90)
8,140 shares@ US$1.31100.0% of flowCommon StockSEC:0001618835-21-000153:0
Canonical exit: 12 Sept 2021 (T+90)
5,000 shares@ US$1.198100.0% of flowCommon StockSEC:0001618835-21-000154:0
Canonical exit: 9 Sept 2021 (T+90)
18,180 shares@ US$1.1430.6% of flowCommon StockSEC:0001618835-21-000150:0
Canonical exit: 9 Sept 2021 (T+90)
10,000 shares@ US$1.02518.0% of flowCommon StockSEC:0001618835-21-000146:0
Canonical exit: 8 Sept 2021 (T+90)
24,500 shares@ US$1.0332.5% of flowCommon StockSEC:0001618835-21-000148:0
Canonical exit: 8 Sept 2021 (T+90)
50,000 shares@ US$1.0320.4% of flowCommon StockSEC:0001618835-21-000147:0
Canonical exit: 8 Sept 2021 (T+90)
31,480 shares@ US$0.8639.8% of flowCommon StockSEC:0001618835-21-000136:0
105,300 shares@ US$0.8635.7% of flowCommon StockSEC:0001618835-21-000133:0
42,280 shares@ US$0.8646.6% of flowCommon StockSEC:0001618835-21-000134:0
42,120 shares@ US$0.8663.4% of flowCommon StockSEC:0001618835-21-000137:0
42,061 shares@ US$0.86100.0% of flowCommon StockSEC:0001618835-21-000135:0
23 of 23 declarations
关于 Evofem Biosciences, Inc.
Evofem Biosciences, Inc. 是一家在美国纳斯达克市场上市的生物制药公司，专注于女性性健康和生殖健康。该公司围绕差异化主张建立了其战略：非激素、按需解决方案，旨在解决避孕和性健康领域未满足的临床需求。Evofem 成立于 2007 年，总部位于加利福尼亚州圣迭戈，于 2018 年上市。它作为一家专业公司而非广泛的制药平台运营，这使其商业足迹比大型多元化制药商更窄，但也拥有更鲜明的产品特性和明确的治疗利基市场。([investor.evofem.com](https://investor.evofem.com/overview/default.aspx?utm_source=openai)) 其核心商业资产是 PHEXXI®，一种用于性交前的处方阴道避孕凝胶。Evofem 将 PHEXXI 定位为一流的、无激素的、按需避孕选择，使女性能够在需要时控制使用，而不是通过每日方案或侵入性手术。2024 年 7 月，该公司通过收购 SOLOSEC® (secnidazole) 2 g 口服颗粒的全球权利扩大了其产品组合，增加了第二款性健康产品，并将收入基础扩展到单一旗舰资产之外。此次收购具有战略重要性，因为它为 Evofem 提供了一个在女性性健康领域更具协同效应的商业平台。([evofem.com](https://www.evofem.com/?utm_source=openai)) 从竞争角度来看，Evofem 在一个拥挤的市场中运营，其中包括主要制药公司、通用避孕选择以及其他非激素或长效替代品。其优势不在于规模，而在于专业化：一种明显差异化的、无激素的产品、以患者为中心的信息，以及围绕自主性和灵活性的专注商业叙事。该公司的机会在很大程度上取决于医生教育、市场准入、处方采用以及在消费者习惯和现有选择根深蒂固的类别中建立认知的能力。主要风险仍然是生物技术商业化面临的常见挑战：产品集中度高、执行风险以及在竞争激烈和成本敏感的环境中维持增长的需求。([evofem.com](https://www.evofem.com/?utm_source=openai)) 从地理上看，Evofem 的商业基础主要在美国，但最近的披露表明，该公司正在通过许可进行谨慎的国际扩张战略。该公司已提及计划在阿拉伯联合酋长国首次推出，并通过被许可方扩大在中东的业务，这可以在不要求大量直接海外足迹的情况下提供增量收益。最近的公司更新还指出，2025 年销售势头有所改善，净销售额同比增长，同时成本纪律更严格，运营绩效有所提高。对于跟踪 SEC Form 4 内部人交易活动的投资者来说，这创造了一个小型医疗保健公司，其运营叙事比往年更清晰，但仍然高度依赖执行和市场接受度。([investor.evofem.com](https://investor.evofem.com/overview/default.aspx?utm_source=openai))
